keynote-189: chemo plus pembrolizumab for nsclc
Published 5 years ago • 159 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
1:25
a real-world analysis on pembro monotherapy versus pembro chemotherapy for never-smoking nsclc
-
4:23
keynote-407: 3-year follow-up of pembrolizumab plus chemo in nsclc
-
2:57
keynote 189: targeting nsclc patients with brain and liver metastases
-
13:06
keynote-189: key summary of a practice-changing trial in advanced non-squamous nsclc (bmic-030)
-
4:05
pembrolizumab chemotherapy in newly diagnosed nsclc
-
5:14
keynote-859: pembrolizumab plus chemotherapy in g/gej adenocarcinoma
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
10:32
evaluation of tmb in keynote-189: pembrolizumab ct vs placebo ct for nonsquamous nsclc
-
1:13
a new standard of care for advanced lung cancer: what’s next for pembrolizumab?
-
7:01
actual use of pembrolizumab and chemotherapy in nsclc
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
1:18
ravi salgia, md, phd, on the ideal patient to receive alimta plus keytruda based on keynote-189
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
4:28
combining chemotherapy and immunotherapy: key trials in lung cancer